In patients with schizophrenia, there appear to be connections between longer duration of illness, raised levels of eotaxin, decreased telomere length, reduced gray matter volume, and impaired episodic memory.
Related content
Dopamine in Parkinson’s Disease and Schizophrenia
Professors Shen-Yang Lim and Christoph Correll explore dopamine’s role in Parkinson’s disease and schizophrenia, discussing treatment evolution, side effects, and parallels between the disorders. Access more resources at Neurotorium.org.
04.12.2024
Parkinson’s Disease
Schizophrenia and Substance Use Disorders Comorbidity
Professors Christoph Correll and Gabriele Fischer discuss the challenges of managing co-occurring schizophrenia and substance use disorders, offering insights into this complex comorbidity.
04.12.2024
Schizophrenia
The Use of Virtual Reality in the Treatment of Severe Mental Illnesses: The Example of Psychosis
The use of virtual reality in the treatment of severe mental illnesses
06.10.2024
Schizophrenia